Chest
Original ResearchAirway DiseasesBurden of Concomitant Asthma and COPD in a Medicaid Population*
Section snippets
Materials and Methods
We conducted a retrospective cohort analysis of patients within a Medicaid population, who had asthma and/or COPD within the study time frame of January 1, 2001, to December 31, 2003. The Maryland Medicaid database retains all claims data for medical inpatient, outpatient, and pharmacy services submitted to the state. More than 445,000 beneficiaries receive Medicaid coverage in Maryland; they account for approximately 10% of the state population. African Americans account for about half,
Results
The total study sample included 9,131 Medicaid patients who met the selection criteria, who were relatively equally distributed across the three cohorts: 3,072 patients (33.64%) were in the asthma cohort, 3,455 patients (37.84%) were in the COPD cohort, and 2,604 patients (28.52%) were in the asthma/COPD cohort. Figure 1 shows a schematic representation of the final cohort determination. One hundred ninety-six patients (5.67%) and 174 patients (5.66%) had the alternative diagnosis during months
Discussion
We have examined a middle-age Medicaid population with the diagnosis of asthma, COPD, or concurrent asthma and COPD, and found that patients with co-occurring disease constitute comparable proportions of the population, as those with either disease alone. However, the incremental utilization for COPD is significant in patients with both asthma and COPD; they consume more medical resources, as compared to those with either COPD or asthma. The existing literature focuses on asthma or on COPD, and
References (18)
- et al.
Asthma-related healthcare services utilization by African-Americans enrolled in West Virginia Medicaid
Respir Med
(2006) - et al.
Understanding of asthma management: Medicaid parents' perspectives
Chest
(2006) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
Assessing the costs of chronic obstructive pulmonary disease: the state Medicaid perspective
Respir Med
(2006) - et al.
A comprehensive study of the direct and indirect costs of adult asthma
J Allergy Clin Immunol
(2003) - et al.
The global burden of asthma: executive summary of the GINA Dissemination Committee report
Allergy
(2004) Morbidity and mortality: 2004 chartbook on cardiovascular, lung, and blood diseases
(2004)COPD: definition
National health interview survey
(2001)
Cited by (128)
GEMA 5.3. Spanish Guideline on the Management of Asthma
2023, Open Respiratory ArchivesEpidemiology of Asthma-Chronic Obstructive Pulmonary Disease Overlap
2022, Immunology and Allergy Clinics of North AmericaAsthma-COPD Overlap: What Are the Important Questions?
2022, ChestCitation Excerpt :Patients with ACO have a greater symptom burden and worse quality of life and experience more frequent and severe respiratory exacerbations requiring hospitalizations than those with asthma or COPD alone.12,24,25,30-33 Thus, it is not surprising that these patients also use more health-care services, leading to substantial economic costs.34 In fact, medical use such as ED visits, admissions, and ICU admission and its associated costs were significantly higher in patients with ACO compared with patients with COPD alone.35
Asthma, chronic obstructive pulmonary disease, tooth loss, and edentulism among adults in the United States: 2016 Behavioral Risk Factor Surveillance System survey
2020, Journal of the American Dental AssociationEpidemiology and risk factors of asthma-chronic obstructive pulmonary disease overlap in low- and middle-income countries
2019, Journal of Allergy and Clinical ImmunologyNonallergic Triggers and Comorbidities in Asthma Exacerbations and Disease Severity
2019, Clinics in Chest Medicine
This work was performed at the University of Maryland School of Pharmacy.
This study was funded by a fellowship grant from GlaxoSmithKline, Inc.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).
- 1
Dr. Shaya, Mr. Du, Dr. Akazawa, Dr. Wang, and Dr. Mapel were sponsored by GlaxoSmithKline, Inc., for this study. Dr. Blanchette and Dr. Dalal are full-time employees of GlaxoSmithKline, Inc. Dr. Scharf has no conflict of interest to disclose.